Alopecia

NEW ORLEANS — Patients who responded to baricitinib treatment for alopecia areata continued to maintain those results with long-term treatment, according to a speaker at the American Academy of Dermatology Annual Meeting.

NEW ORLEANS —Pruritus could be a reliable indicator of inflammation in central centrifugal cicatricial alopecia, according to a poster presented here.

Prolonged use of baricitinib increased the drug’s efficacy in the treatment of adults with severe alopecia areata, according to two phase 3 trials.

Alopecia prevalence and incidence rates increased between 2016 and 2019, a trend that may be reflective of a growing disease burden or simply due to more patients seeking care, according to a study.

Transgender and gender-diverse patients receiving masculinizing hormone therapy have 2.5 times the rate of androgenetic alopecia incidences compared with cisgender women, according to a study.

MIAMI BEACH, Fla. — The past year has seen explosive development in Janus kinase inhibitors for dermatologic conditions, and it is possible they could continue to have indications throughout the specialty, according to a speaker here.

Prevalence of depressive and anxiety disorders, as well as related symptoms, was greater in patients with alopecia areata compared with the general population, according to a study.

WAILEA, Hawaii — Janus kinase inhibitors could be the future of alopecia areata treatment in children if research proves them to be safer than current warnings suggest, according to a presenter at the Maui Derm meeting.

Sun Pharma has reached a definitive agreement to acquire outstanding shares of Concert Pharmaceuticals Inc. for $576 million in equity value, according to a press release issued by the two companies.

From Feb. 9 to 12 at Miami Beach, Healio will be covering the latest updates and brand-new topics at 2023 South Beach Symposium, a premier medical and aesthetic dermatology conference.